



20 July 2023

Shareholder Update



Myopharm™ signs non-binding term sheet to acquire 100% of TriGlytza™ rights.

- Myopharm™ to purchase of 100% of TriGlytza™ (RK-01) intellectual property.
- Acquisition to bolster Myopharm's metabolic and diabetes pipeline.
- Purchase includes TriGlytza™ (RK-01) US Patent and IND.

Myopharm Limited is pleased to announce the acquisition of TriGlytza™ (RK-01) a combination beta-cell-centric inflammatory pathway technology, originally developed by Arkay Therapeutics LLC.

The purchase includes the United States Patent US 9,839,644 B2 and the FDA approved Investigational New Drug (IND) 136121 covering all 68 metabolic claims approved and all intellectual property.

Myopharm to undertake development of a Type 2 Diabetes combination drug, with the prescription drug market predicted to be worth \$96b by 2029. TriGlytza™ is anticipated to benefit patients as a standalone or adjunct therapy or for the large cohort of Type 2 diabetics who are intolerant of first line treatment such as Metformin.

Myopharm continues to assess and execute growth opportunities associated with new product launches in Australian pharmacy and hospital channels and the overseas markets that develop and support global market access for the Company. We are preparing for a period of significant activity and look forward to updating Shareholders.

TriGlytza™ (RK-01)

The scientific rationale and the product concept for TriGlytza™ for treating Type 2 diabetes are based on the pancreatic 'beta-cell-centric' concept developed by Ravi Kumar, Ph.D. and, Stan Schwartz, MD, a renowned endocrinologist and an Emeritus Associate Clinical Professor of Medicine, University of Pennsylvania. Dr. Schwartz proposed treating patients

by stratifying them based on the defects and the mechanisms that contribute to hyperglycaemia and beta cell dysfunction, the core defect (Schwartz, S.S. et al. Diabetes Care 2016; 39: 179-186).

TriGlytza™ targets the self-reinforcing cascade of multidimensional and unifying inflammatory pathways that originate from several clinically relevant cell types. As supported by the PoC clinical studies with small patient populations, it is expected to restore beta cell function and/or prevent beta cell failure, and maintain a state of insulin sufficiency.

TriGlytza™ is an innovative, patient-centric drug. Unlike the currently marketed drugs which treat Type 2 diabetes in isolation, it treats the disease in the context of comorbidities and coexisting conditions by targeting the multidimensional pathophysiology. It is custom-designed and formulated to prevent beta cell failure, decrease insulin resistance and prevent failure of Metformin treatment.

Type 2 diabetes is a complex metabolic disorder characterized by pancreatic beta cell failure in the setting of insulin resistance. Currently marketed "me-too" drugs are inadequate in filling one of the most important gaps in the space: sustained glycaemic control, with a focus on preserving beta cell function and decreasing insulin resistance. Type 2 diabetes continues to be an unmet medical need because almost 50% of over 1 million newly diagnosed patients experienced primary failure with Metformin (the current first-line of therapy) and secondary failure with second and third add-on antidiabetes drugs from 2005 to 2016 in real-world clinical practice in the United States (Montvida, O. et al. Diabetes Care 2018).

Myopharm CEO and Executive Chair Karinza Phoenix said *"with the recent Australian Government inquiry into Diabetes Mellitus and an Australian wide focus on Beta Cell dysfunction technologies acquisition of TriGlytza™ places Myopharm at the forefront of diabetes innovation."*

Karinza Phoenix

Myopharm Limited

Executive Chair & Chief Executive Officer

kphoenix@myopharm.com

Release authorised by the Executive Chair and Chief Executive Officer of Myopharm Limited

For Investor Enquiries, please get in touch with us at Investor@myopharm.com.

About Myopharm

Website: www.myopharm.com

Myopharm is a diabetes focused company developing innovative diabetes solutions that delay disease progression and improve quality of life. At Myopharm, our research and development teams develop clinically validated pharmaceutical products based on an innovative multitarget approach enabled by leading scientists from a high level of evidence.

Our aim is to reduce metabolic diseases that millions of people worldwide are at risk of.

International Diabetes Federation released an alarming growth rate in the prevalence of diabetes, with over 800 million adults worldwide living with diabetes. Closer to home, diabetes is now the fastest-growing chronic condition in Australia.